Caterina Lonati Selected Research

4-Nle-7-Phe-alpha- MSH

1/2021	NDP-MSH treatment recovers marginal lungs during ex vivo lung perfusion (EVLP).
3/2012	Protective action of NDP-MSH in experimental subarachnoid hemorrhage.
1/2010	The peptide NDP-MSH induces phenotype changes in the heart that resemble ischemic preconditioning.
3/2007	Production and effects of alpha-melanocyte-stimulating hormone during acute lung injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Caterina Lonati Research Topics

Disease

9	Inflammation (Inflammations) 01/2022 - 01/2006
5	Brain Death (Brain Dead) 10/2021 - 01/2006
3	Lung Injury 01/2022 - 03/2007
3	Ischemia 01/2022 - 12/2014
2	Pneumonia (Pneumonitis) 01/2021 - 10/2018
2	Reperfusion Injury 01/2010 - 01/2010
1	Overweight 05/2022
1	Insulin Resistance 05/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2022
1	Weight Loss (Weight Reduction) 05/2022
1	Obesity 05/2022
1	Chronic Disease (Chronic Diseases) 05/2022
1	Weight Gain 02/2022
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2022
1	Hypercapnia 01/2022
1	Muscular Atrophy (Muscle Atrophy) 01/2021
1	Wounds and Injuries (Trauma) 01/2021
1	Migraine Disorders (Migraine) 01/2020
1	Thrombosis (Thrombus) 01/2020
1	Cytokine Release Syndrome 01/2020
1	Virus Diseases (Viral Diseases) 01/2020
1	Death (Near-Death Experience) 12/2019
1	Muscular Dystrophies (Muscular Dystrophy) 10/2018
1	Fatigue 10/2018
1	Primary Graft Dysfunction 10/2018
1	Osteoarthritis 06/2015
1	Osteosarcoma (Osteogenic Sarcoma) 03/2012
1	Hemorrhagic Shock 03/2012
1	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 03/2012
1	Hemorrhage 03/2012
1	Fever (Fevers) 01/2010
1	Shock 01/2010
1	Acute Lung Injury 03/2007
1	Pulmonary Edema 03/2007
1	Edema (Dropsy) 03/2007

Drug/Important Bio-Agent (IBA)

8	MelanocortinsIBA 01/2021 - 01/2006
4	4-Nle-7-Phe-alpha- MSHIBA 01/2021 - 03/2007
3	dicarboxydine (DCD)IBA 10/2021 - 12/2019
2	Melanocortin Receptors (Melanocortin Receptor)IBA 01/2020 - 01/2006
2	Peptides (Polypeptides)IBA 03/2012 - 03/2007
2	alpha-MSHIBA 01/2010 - 03/2007
1	Vitamin D FDA LinkGeneric 05/2022
1	hydroxide ionIBA 05/2022
1	Biomarkers (Surrogate Marker)IBA 05/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 02/2022
1	Flavin Mononucleotide (FMN)IBA 02/2022
1	Glucose (Dextrose)FDA LinkGeneric 02/2022
1	MicronutrientsIBA 01/2022
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 01/2022
1	EnzymesIBA 10/2021
1	InterleukinsIBA 01/2021
1	Melanocyte-Stimulating Hormones (MSH)IBA 01/2021
1	LigandsIBA 01/2020
1	Amino Acids FDA Link 10/2018
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 10/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2018
1	Prostaglandins DIBA 10/2018
1	CytokinesIBA 06/2015
1	Activating Transcription Factor 3IBA 03/2012
1	Heme Oxygenase (Decyclizing) (Heme Oxygenase)IBA 03/2012
1	Bleomycin (Blenoxane)FDA LinkGeneric 03/2007
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2007
1	Complementary DNA (cDNA)IBA 07/2006
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2006
1	Type 1 Melanocortin ReceptorIBA 01/2006
1	Messenger RNA (mRNA)IBA 01/2006

Therapy/Procedure

6	Transplantation 01/2022 - 01/2010
2	Ligation 01/2022 - 10/2021
2	Artificial Respiration (Mechanical Ventilation) 01/2022 - 10/2021
2	Positive-Pressure Respiration (Positive End-Expiratory Pressure) 10/2021 - 12/2014
2	Warm Ischemia 01/2021 - 12/2014
2	Lung Transplantation 10/2018 - 12/2014
1	Caloric Restriction 05/2022
1	Extracorporeal Membrane Oxygenation 01/2022
1	Liver Transplantation 01/2020
1	Therapeutics 01/2020
1	General Anesthesia 03/2012